These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
592 related articles for article (PubMed ID: 15466215)
21. The increased expression of peroxisome proliferator-activated receptor-gamma1 in human breast cancer is mediated by selective promoter usage. Wang X; Southard RC; Kilgore MW Cancer Res; 2004 Aug; 64(16):5592-6. PubMed ID: 15313896 [TBL] [Abstract][Full Text] [Related]
23. A role for CCAAT/enhancer binding protein beta-liver-enriched inhibitory protein in mammary epithelial cell proliferation. Zahnow CA; Cardiff RD; Laucirica R; Medina D; Rosen JM Cancer Res; 2001 Jan; 61(1):261-9. PubMed ID: 11196172 [TBL] [Abstract][Full Text] [Related]
24. Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis. Medina D; Kittrell FS; Hill J; Shepard A; Thordarson G; Brown P Cancer Res; 2005 Apr; 65(8):3493-6. PubMed ID: 15833886 [TBL] [Abstract][Full Text] [Related]
25. Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice. Sevenich L; Werner F; Gajda M; Schurigt U; Sieber C; Müller S; Follo M; Peters C; Reinheckel T Oncogene; 2011 Jan; 30(1):54-64. PubMed ID: 20818432 [TBL] [Abstract][Full Text] [Related]
26. SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors. Tzeng YJ; Zimmermann C; Guhl E; Berg B; Avantaggiati ML; Graessmann A Oncogene; 1998 Apr; 16(16):2103-14. PubMed ID: 9572491 [TBL] [Abstract][Full Text] [Related]
27. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Sarkisian CJ; Keister BA; Stairs DB; Boxer RB; Moody SE; Chodosh LA Nat Cell Biol; 2007 May; 9(5):493-505. PubMed ID: 17450133 [TBL] [Abstract][Full Text] [Related]
28. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874 [TBL] [Abstract][Full Text] [Related]
29. Peroxisome proliferator-activated receptor gamma and cancers. Koeffler HP Clin Cancer Res; 2003 Jan; 9(1):1-9. PubMed ID: 12538445 [TBL] [Abstract][Full Text] [Related]
30. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Yin Y; Russell RG; Dettin LE; Bai R; Wei ZL; Kozikowski AP; Kopelovich L; Glazer RI Cancer Res; 2005 May; 65(9):3950-7. PubMed ID: 15867396 [TBL] [Abstract][Full Text] [Related]
31. Functional mammary gland development and oncogene-induced tumor formation are not affected by the absence of the retinoblastoma gene. Robinson GW; Wagner KU; Hennighausen L Oncogene; 2001 Oct; 20(48):7115-9. PubMed ID: 11704837 [TBL] [Abstract][Full Text] [Related]
32. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus. Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997 [TBL] [Abstract][Full Text] [Related]
33. Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice. Kirma N; Gill K; Mandava U; Tekmal RR Cancer Res; 2001 Mar; 61(5):1910-8. PubMed ID: 11280746 [TBL] [Abstract][Full Text] [Related]
34. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379 [TBL] [Abstract][Full Text] [Related]
35. The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer. Lewis BC; Klimstra DS; Varmus HE Genes Dev; 2003 Dec; 17(24):3127-38. PubMed ID: 14681205 [TBL] [Abstract][Full Text] [Related]
36. Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. Xu Y; Iyengar S; Roberts RL; Shappell SB; Peehl DM J Cell Physiol; 2003 Jul; 196(1):131-43. PubMed ID: 12767049 [TBL] [Abstract][Full Text] [Related]
37. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. Mehta RG; Williamson E; Patel MK; Koeffler HP J Natl Cancer Inst; 2000 Mar; 92(5):418-23. PubMed ID: 10699072 [TBL] [Abstract][Full Text] [Related]
38. Transgenic Polyoma middle-T mice model premalignant mammary disease. Maglione JE; Moghanaki D; Young LJ; Manner CK; Ellies LG; Joseph SO; Nicholson B; Cardiff RD; MacLeod CL Cancer Res; 2001 Nov; 61(22):8298-305. PubMed ID: 11719463 [TBL] [Abstract][Full Text] [Related]
39. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Zinser GM; Welsh J Carcinogenesis; 2004 Dec; 25(12):2361-72. PubMed ID: 15333467 [TBL] [Abstract][Full Text] [Related]
40. The caM kinase, Pnck, is spatially and temporally regulated during murine mammary gland development and may identify an epithelial cell subtype involved in breast cancer. Gardner HP; Ha SI; Reynolds C; Chodosh LA Cancer Res; 2000 Oct; 60(19):5571-7. PubMed ID: 11034105 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]